Kymera Therapeutics stock: Three discovery projects halted after contract ends
Published on 11/19/2026 at 04:00 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSKymera project halt raises pipeline questions
- Kymera halted three individual research projects with SyntekaBio after reviewing research results and business priorities.
- The contract terminations are scheduled to take effect on November 30, while the companies' master service agreement remains in place.
- The decision comes ahead of expected clinical data from Kymera's KT-621 program by year-end 2026.
Kymera Therapeutics halted three research projects with SyntekaBio after reviewing project results and business priorities, according to E-Daily. SyntekaBio reported the contract terminations on November 16, 2026, after receiving Kymera's notice on November 14.
Three research projects discontinued
The terminated agreements covered manufacturing and clinical-development services as well as drug-candidate discovery. The combined contract amount was 533.92 million South Korean won, while performance payments totaling USD 420,000 will not be received by SyntekaBio.
The termination is scheduled to take effect on November 30, ahead of the original contract end date. The companies will nevertheless maintain their master service agreement, leaving the broader commercial relationship in place.
Pipeline focus remains ahead
The project halt adds a setback to Kymera's external research activity as investors await further updates from its internal clinical pipeline. The company's KT-621 BROADEN2 Phase 2b trial is expected to deliver topline data by the end of 2026, according to the company's third-quarter release summarized in the current market coverage.
Kymera's drug-discovery model
Kymera Therapeutics is a U.S. biotechnology company focused on drug discovery. Its work with SyntekaBio included compound discovery and manufacturing and clinical-development services. The disclosed project termination does not end the master service agreement between the two companies.
Kymera Therapeutics at a glance
- Company: Kymera Therapeutics, Inc.
- ISIN: US5015751044
- Ticker: KYMR
- Event date: November 16, 2026
- Contract status: Termination scheduled for November 30, 2026
Kymera's home-market environment is represented by the S&P 500.
More news and analyses on Kymera Therapeutics stock are available here.
